scholarly journals 429 Identification of clinicopathological prognostic factors in recurrent endometrial cancer

2020 ◽  
Author(s):  
Y Koike ◽  
M Takenaka ◽  
J Suzuki ◽  
Y Shoburu ◽  
K Tomita ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Recurrent Endometrial Cancer

Prognostic factors associated with survival following platinum-based therapy in advanced/recurrent endometrial cancer

2019 ◽  
Vol 154 ◽  
pp. 238
Author(s):  
K.G. Essel ◽  
M.H. Vetter ◽  
D.W. Doo ◽  
M. Greenwade ◽  
M. Machiorlatti ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Factors Associated ◽  
Recurrent Endometrial Cancer

Prognostic factors associated with survival following platinum based therapy in advanced/recurrent endometrial cancer

2019 ◽  
Vol 154 (1) ◽  
pp. e22-e23
Author(s):  
K. Essel ◽  
M. Vetter ◽  
D. Doo ◽  
M. Greenwade ◽  
S. Vesely ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Factors Associated ◽  
Recurrent Endometrial Cancer

scholarly journals IMPACT OF HORMONAL BIOMARKERS ON RESPONSE TO HORMONAL THERAPY IN ADVANCED AND RECURRENT ENDOMETRIAL CANCER:

2021 ◽  
Author(s):  
Willem Jan VAN WEELDEN ◽  
Roy I. LALISANG ◽  
Johan BULTEN ◽  
Kristina LINDEMANN ◽  
Heleen J. VAN BEEKHUIZEN ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Hormonal Therapy ◽  
Recurrent Endometrial Cancer

Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel

2000 ◽  
Vol 160 (1) ◽  
pp. 9-12 ◽  
Author(s):  
Shunichiro Ota ◽  
Toru Sugiyama ◽  
Kimio Ushijima ◽  
Kan Komai ◽  
Keizo Fujiyoshi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Successful Treatment ◽  
Weekly Paclitaxel ◽  
Recurrent Endometrial Cancer

Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study

2021 ◽  
Vol 161 (1) ◽  
pp. 104-112
Author(s):  
Robert L. Coleman ◽  
Wei Hu ◽  
Pamela Soliman ◽  
Alpa Nick ◽  
Pedro T. Ramirez ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Advanced Stage ◽  
Translational Study ◽  
Recurrent Endometrial Cancer

Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis

2021 ◽  
Author(s):  
David A. Barrington ◽  
Paulina J. Haight ◽  
Cody Calhoun ◽  
Crystal Tubbs ◽  
David E. Cohn ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Recurrent Endometrial Cancer
Sign in / Sign up

Export Citation Format

Share Document